Karyopharm and Collaborators Awarded Grant for ALS Research
15 déc. 2016 07h30 HE
|
Karyopharm Therapeutics
- Target ALS Consortium Grants $900,000 in Research Funding for KPT-350 in ALS - - Fifth Grant Awarded in Support of KPT-350 as a Potential ALS Treatment Option - NEWTON, Mass., Dec. 15,...
Karyopharm Presents Updated Phase 1b STOMP Data at the American Society of Hematology 2016 Annual Meeting
05 déc. 2016 17h45 HE
|
Karyopharm Therapeutics
- STOMP Data Continues to Demonstrate High Response Rates in Patients with Heavily Pretreated Multiple Myeloma When Selinexor Is Combined with Bortezomib and Pomalidomide - - Company to Host Dinner...
Karyopharm Presents Updated Phase 2b STORM Data at the American Society of Hematology 2016 Annual Meeting
04 déc. 2016 19h30 HE
|
Karyopharm Therapeutics
- Data Continue to Reinforce the Efficacy and Safety of Selinexor in Patients with Heavily Pretreated Refractory Multiple Myeloma - - Company to Host Dinner Reception and Webcast Event with...
Karyopharm Presents Updated Phase 2 SAIL Relapsed/Refractory AML Clinical Data at the American Society of Hematology 2016 Annual Meeting
04 déc. 2016 12h30 HE
|
Karyopharm Therapeutics
- Data Demonstrate Robust Response Rates Enabling Transplantation or Donor Lymphocyte Infusions in Patients with Heavily Pretreated Acute Myeloid Leukemia - NEWTON, Mass., Dec. 04, 2016 (GLOBE...
Karyopharm and the Multiple Myeloma Research Foundation Announce Panel Discussion Featuring Leading Multiple Myeloma Thought Leaders
30 nov. 2016 07h30 HE
|
Karyopharm Therapeutics
NEWTON, Mass. and NORWALK, Conn., Nov. 30, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, together with the Multiple Myeloma Research...
Karyopharm to Present at the Jefferies 2016 London Healthcare Conference
10 nov. 2016 07h30 HE
|
Karyopharm Therapeutics
NEWTON, Mass., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief...
Karyopharm Reports Third Quarter 2016 Financial Results and Highlights Recent Progress
07 nov. 2016 16h05 HE
|
Karyopharm Therapeutics
− Recent Utilization of ATM Financing Facility Nets Proceeds of $47 million; Extends Cash Runway to end of 2018, Beyond STORM Expansion Data Readout – − Updated Clinical Data from STORM and STOMP...
Karyopharm to Present Updated Phase 2b STORM and Phase 1b STOMP Clinical Data at the American Society of Hematology 2016 Annual Meeting
03 nov. 2016 09h43 HE
|
Karyopharm Therapeutics
- Diverse Data Continue to Reinforce the Efficacy and Safety of Selinexor in Patients with Heavily Pretreated Refractory Multiple Myeloma - - Twenty-one Abstracts Selected, Including Nine Oral...
Karyopharm to Ring the Nasdaq Stock Market Closing Bell
02 nov. 2016 07h30 HE
|
Karyopharm Therapeutics
NEWTON, Mass., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that company executives, including founder...
Karyopharm to Report Third Quarter 2016 Financial Results on November 7, 2016
31 oct. 2016 07h30 HE
|
Karyopharm Therapeutics
NEWTON, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report third quarter 2016...